This randomized clinical trial compared how effectively high-dose, targeted radiation therapy versus no treatment (observation) among 54 men prevented the progression over six months of recurrent hormone-sensitive prostate cancer that has metastasized to a small number of sites in the body.
Highly focused, intense doses of radiation called stereotactic ablative radiation (SABR) may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.
Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and 'second generation' approaches are needed. Now, a team of Penn State engineers may have a way to predict which mutations will occur in people, creating an easier path to create effective pharmaceuticals.
Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Researchers at the University of East Anglia have discovered why some prostate cancers are more aggressive, spread to different parts of the body, and ultimately cause death. It is hoped that the discovery, published today, could transform patient treatment.
A researcher at James Cook University in Australia says scientists have found that exercise can be beneficial to patients as they begin treatment for prostate cancer.
Pairing chemotherapy nanodrugs with a nutritional supplement can lessen devastating side-effects while reducing the amount of the expensive drugs needed to treat cancer according to a study from Carnegie Mellon University and Taiwan's National Health Research Institutes. In addition, pretreatment with the supplement promotes the production of tumor-killing macrophages, making it a promising complement and supplement to existing chemotherapies.
Researchers of Sechenov University together with their colleagues from Australia used the microfluidics technology to develop a device able to isolate cancer cells from urine of patients with prostate cancer. The study showed high sensitivity and specificity of the new method in diagnosing prostate cancer. The results obtained were published in Cancers.
Unnecessary prostate cancer biopsies could be reduced by 60% thanks to new research from the University of East Anglia. Researchers have developed new methods to identify biomarkers for prostate cancer by combining information from multiple parts of urine samples. It is hoped that the breakthrough could help large numbers of men avoid an unnecessary initial biopsy.